Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
TipRanksApr 8 12:10 ET
Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Facts
RTTNewsApr 8 09:08 ET
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib,
GlobeNewswireApr 8 08:30 ET
Insider Buys Additional US$51k In Nuvectis Pharma Stock
Yahoo FinanceMar 21 06:08 ET
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$51,450 in Common Stocks
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 5,000 shares of Common Stocks on Mar 18, 2024 at an average price of $10.29 for a total value of $51,450.Source: Announcement What is s
moomoo NewsMar 19 08:39 ET
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati
GlobeNewswireMar 19 08:00 ET
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious
GlobeNewswireMar 15 08:00 ET
Express News | Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Moomoo 24/7Mar 14 09:47 ET
Nuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer Treatment
By Chris Wack Nuvectis Pharma shares were up 11% in premarket trading after the company said it saw positive preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with plati
WSJMar 14 09:19 ET
Nuvectis Reports Promising Ovarian Cancer Drug Trial Data
Nuvectis Pharma, Inc. (NASDAQ: NVCT) has announced preliminary results from its Phase 1b clinical trial of NXP800, showcasing encouraging data in the treatment of platinum-resistant, ARID1a-mutated ovarian cancer.
Investing.com Mar 14 09:10 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved
BenzingaMar 14 09:06 ET
Nuvectis Pharma Announces Encouraging Preliminary Data From the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious Condition
GlobeNewswireMar 14 09:00 ET
Nuvectis Pharma GAAP EPS of -$1.43 Beats by $0.16
Seeking AlphaMar 6 13:07 ET
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 EPS $(1.43) Vs $(1.51) YoY
NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year endedDecember 31, 2023December 31, 2022OPERATING EXPENSES:Research and
BenzingaMar 5 08:21 ET
Nuvectis Pharma FY23 Loss $22.3M >NVCT
Nuvectis Pharma FY23 Loss $22.3M >NVCT
Dow JonesMar 5 08:03 ET
Press Release: Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights -- NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant,
Dow JonesMar 5 08:00 ET
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) CEO Ron Bentsur Is the Most Upbeat Insider, and Their Holdings Increased by 42% Last Week
Key Insights Nuvectis Pharma's significant insider ownership suggests inherent interests in company's expansion 54% of the business is held by the top 4 shareholders Ownership research along with
Simply Wall StMar 2 07:01 ET
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
GlobeNewswireFeb 9 08:00 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersCelularity (NASDAQ:CELU) shares moved upwards by 44.7% to $0.27 during Thursday's regular session. The company's market cap stands at $52.8 million. NovoCure (NASDAQ:NVCR) shares increased by 2
BenzingaJan 18 12:31 ET
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
GlobeNewswireJan 3 08:00 ET
No Data
No Data